CCM>Market Reports>
| No. | 05P022 | Some Active Pharmaceutical Ingredients & Their Manufacturers in China |
About This Report:
| Brief introduction: | This report summarizes the overall situation of some active pharmaceuticals ingredients, totally 45 hot items in which most foreign companies show interest, each of which being discussed from aspects of number of manufacturers, capacity, actual production level, specification, price, etc. Extensive telephone interview has been carried out with all the manufacturers of each ingredient to obtain the actual situation, market view, strategy & plan, etc., aiming to uncover the strengths / weakness of main (potential) Chinese producers of future generic active pharmaceutical ingredients (API). The aim of this report is to provide the findings of the "Molecule Hunt" - preliminary advice on who is producing (commercial, medium, lab scale or otherwise) with some details about the various makers of the 45 chosen molecules, and to provide preliminary understanding on the development situation of these molecules, and hope to conclude the trend of Chinese pharmaceutical ingredient industry. All the data come from reliable sources and has been confirmed with both manufacturers and legal authorities, filtered by scientific methods and compiled systematically. | |
| Language version: | English | |
| Document type: | PDF document | |
| For ready report -- | ||
| Finished in: | Jul. 2001 | |
| Total pages: | 128 | |
| Delivery time: | 6-9 working days | |
| Price: | USD5,000.00/copy | |
| For update report -- | ||
| Delivery time: | 13-21 working dasys | |
| Price: | USD8,000.00/copy | |
Main Content in the Update Report:
| - Executive Summary | |
| - Active Items That Are Produced in China | |
| 1) Alendronate | |
| 2) Amlodipine | |
| 3) Azithromycin | |
| 4) Celecoxib | |
| 5) Ceftriaxone | |
| 6) Ciprofloxacin | |
| 7) Clarithromycin | |
| 8) Enalapril | |
| 9) Epoetin Alpha | |
| 10) Famotidine | |
| 11) Fluconazole | |
| 12) Fluoxetine | |
| 13) Glipizide | |
| 14) Interferon | |
| 15) Lansoprazole | |
| 16) Lisinopril | |
| 17) Metformin | |
| 18) Omeprazole | |
| 19) Paclitaxel | |
| 20) Pantoprazole | |
| 21) Pioglitazone | |
| 22) Pravastatin | |
| 23) Raloxifene | |
| 24) Rofecoxib | |
| 25) Salmeterol | |
| 26) Sildenalfil | |
| 27) Simvastatin | |
| Potential Items That Maybe Produced in the Near Future | |
| 1) Candesartan | |
| 2) Cefuroxime | |
| 3) Estrogen | |
| 4) Sumatriptan | |
| Potential Itemsin the Chinese Marketplace | |
| 1) Atovastatin | |
| 2) Bupropion | |
| 3) Cetirizine | |
| 4) Fluticasone | |
| 5) Loratidine | |
| 6) Olanzapine | |
| 7) Paroxetine hemihydrate | |
| 8) Risperidone | |
| 9) Rosiglitazone | |
| 10) Sertraline | |
| 11) Tolterodine | |
| 12) Trovafloxacin | |
| 13) Venlafaxine | |
| 14) Losartan | |
| Key factors and driven forces for the development in China; | |
| Futuer forecast on API industry in the next 5-10 years; | |
| Conclusion & Recommendation | |
| Appendix: Introduction to Some Active Manufacturers |
Part of Report:
......
(The rest content of this report is omitted.)
Remark:
If you are not satisfied with the above main content, or if you would like to add additional requirements to the mentioned subject, or if you could not find your interested item(s) via the search engine, you are advised to go to Single-Client Services and Advisor, or Contact Us.